An Open-Label Study of the Safety and Efficacy of Atiprimod Treatment for Patients with Advanced Cancer.

Trial Profile

An Open-Label Study of the Safety and Efficacy of Atiprimod Treatment for Patients with Advanced Cancer.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 14 Feb 2012

At a glance

  • Drugs Atiprimod (Primary)
  • Indications Cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 14 Feb 2012 Actual patient number 28 added as reported by ClinicalTrials.gov (NCT00430014).
    • 14 Feb 2012 Planned end date changed from 1 Mar 2014 to 1 Feb 2012 as reported by ClinicalTrials.gov (NCT00430014).
    • 14 Feb 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov (NCT00430014).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top